About this trial
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.
It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.
Eligibility criteria
Qualifiers
Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months
Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics
There is no obvious suspicion of autoimmune encephalitis
Written informed consent and sera are obtained
Disqualifiers
Patients have other etiology of seizures, such as structure, infection, genetics and metabolism.
Written informed consent are not obtained
Loss of follow-up
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Shen Chun-Hong
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor institution